| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 2.36% |
| NAV | ₹17.40 (30 Oct 2020) |
|---|---|
| Fund Started | 30 Nov 2018 |
| Fund Size | ₹833 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Cipla Ltd. | Healthcare | Equity | 9.6% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 9.1% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 7.8% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 5.6% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 5.4% |
| Torrent Pharmaceuticals Ltd. | Healthcare | Equity | 4.8% |
| Procter & Gamble Health Ltd. | Healthcare | Equity | 4.4% |
| JB Chemicals & Pharmaceuticals Ltd. | Healthcare | Equity | 4.0% |
| ICICI Lombard General Insurance Company Ltd. | Financial | Equity | 3.8% |
| Max Healthcare Institute Ltd. | Healthcare | Equity | 3.3% |
DSP Healthcare Fund Regular Growth is a Equity Mutual Fund Scheme launched by DSP Mutual Fund. This scheme was made available to investors on 30 Nov 2018. Aditya Khemka is the Current Fund Manager of DSP Healthcare Fund Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹833 Cr and the Latest NAV as of 30 Oct 2020 is ₹17.40.
The DSP Healthcare Fund Regular Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 500. Exit load of 1% if redeemed within 12 months.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.